The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

NCT02283476 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Endostar continuous intravenous infusion
DRUG: Endostar routine intravenous infusion
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.